Advancing rare disease measurement through the Rare Disease Clinical Outcome Assessment Consortium
Naomi Knoble1, Lindsey T Murray2
1Division of Clinical Outcome Assessment, Office of Drug Evaluation Science, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Abstract:
There is a significant unmet need to develop and evaluate new treatments for people living with one of approximately 8000 rare diseases. Well-known difficulties in conducting clinical trials (e.g., small samples, wide geographic distribution, heterogeneous symptoms) and developing products for these rare indications persist. Identifying outcomes in rare disease clinical trials remains a hurdle that contributes to the challenges for drug and gene therapy development due to uncertainty about what aspects of a condition to measure for safety and efficacy and often with no regulatory approval precedent. To accelerate rare disease treatments by advancing outcomes measurement, the US Food and Drug Administration (FDA) funded a cooperative agreement to establish the Rare Disease COA Consortium (RD-COAC) in 2019. The RD-COAC officially launched on January 1, 2022, with the mission to enable pre-competitive, multi-stakeholder collaboration aimed at identifying scientifically sound tools and methodologies for collecting clinically meaningful and patient-centric outcomes data in treatment trials for rare diseases. The RD-COAC has four complementary workstreams to advance COA measurement for rare disease clinical trials: (1) Rare Disease COA Resource; (2) Advancing COA Measurement Topic-Focused Working Groups; (3) Rare Disease Discussion Sessions for pre-competitive collaboration and shared learnings among RD-COAC members; and (4) Dissemination. This review provides an overview of the RD-COAC's activities to date, as well as future directions and opportunities to collaborate.
Insights
Developing treatments for rare diseases is challenging due to small patient groups and unclear outcomes. The Rare Disease Clinical Outcome Assessment (COA) Consortium (RD-COAC) aims to improve data collection for rare disease clinical trials.
Area of Science:
- * Clinical trial methodology
- * Rare disease research
- * Patient-reported outcomes
Background:
- * Approximately 8000 rare diseases present significant unmet needs for new treatments.
- * Clinical trials for rare diseases face challenges like small sample sizes, geographic dispersion, and symptom heterogeneity.
- * Identifying appropriate outcome measures for safety and efficacy in rare disease trials is a persistent hurdle.
Purpose of the Study:
- * To accelerate the development of rare disease treatments by advancing outcomes measurement.
- * To establish the Rare Disease Clinical Outcome Assessment (COA) Consortium (RD-COAC) through FDA funding.
- * To foster pre-competitive, multi-stakeholder collaboration for identifying sound tools and methodologies for collecting meaningful, patient-centric outcomes data.
Main Methods:
- * The RD-COAC was established in 2019 and launched in 2022.
- * Four workstreams are in place: Rare Disease COA Resource, Topic-Focused Working Groups, Discussion Sessions, and Dissemination.
- * Focus on collaboration to identify scientifically sound tools and methodologies for COA measurement.
Main Results:
- * Overview of RD-COAC activities to date.
- * Identification of scientifically sound tools and methodologies for COA measurement.
- * Facilitation of pre-competitive collaboration and shared learning among stakeholders.
Conclusions:
- * The RD-COAC is actively working to address the challenges in rare disease clinical trial outcomes measurement.
- * Collaboration is key to advancing the collection of clinically meaningful and patient-centric outcomes data.
- * Future directions and collaboration opportunities are outlined to further accelerate rare disease treatment development.
More Related Videos
08:36The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
Published on: July 28, 2022
06:52Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
Related Concept Videos
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
01:21Cancer Survival Analysis
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:24Kaplan-Meier Approach
01:29Nursing Assessment
The nurse collects all aspects of the patient's health in the initial assessment, establishing priorities for ongoing focused assessments...